BBIO · Healthcare
Bridgebio Pharma Inc
26/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
34
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$16.4B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About BRIDGEBIO PHARMA INC
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3…
Who's behind the signal
Every informed buyer we can see on BBIO, across all three feeds.
Hedge funds · 6
Citadel Advisors
Increased +355%
D.E. Shaw & Co
Increased +15%
Bridgewater Associates (Dalio)
Increased +501%
Millennium Management (Englander)
Increased +1631%
AQR Capital Management
Increased +19%
Viking Global Investors
Decreased −18%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
BRIDGEBIO PHARMA INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
5
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+355%
0.2% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+15%
0.2% of D.E. Shaw & Co's portfolio
Trust weight: 1.3×
% of portfolio
0.1%
Position change
+501%
0.1% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+1631%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+19%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.5×
% of portfolio
2.5%
Position change
−18%
2.5% of Viking Global Investors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to BRIDGEBIO PHARMA INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BRIDGEBIO PHARMA INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime